A prospective, randomized, comparative, clinical studyto assess the safety and performance of Cross-linked Hyaluronic Acid- Dermalfiller in people with all skin types, who need Lip Enhancement, Cheek boneAugmentation and Nasolabial fold improvement
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 发起方
- 入组人数
- 186
- 试验地点
- 1
- 主要终点
- The primary efficacy endpoint is responder rate in GAIS Score from Day 0 to 12 Months and
研究概览
简要总结
This is a prospective, randomized, comparative, clinical study to assess the safety and performance of Cross-linked Hyaluronic Acid- Dermal filler in people with all skin types, who need Lip Enhancement, Cheek bone Augmentation and Nasolabial fold improvement.
Primary objective of this study
- To Assess and compare the safety and performance of
Crosslinked HA (Biotech’s Dermal filler compared to
Juvederm Voluma XC for cheekbone Augmentation,
Juvederm Ultra Plus XC for nasolabial fold treatment and
Juvederm Volift for Lip Enhancement) for subjects with
a) Cheek bone Augmentation
b) Nasolabial fold improvement
c) Lip Enhancement
- Incidence of all adverse events at 6 and 12 months and any
systemic adverse events
and Secondary Objectives of this study
-
Assess dermal filler success in overall face improvement.
-
Evaluate and compare efficacy of Cross-linked HA
(Biotech’s dermal filler and Juvederm Voluma XC in Cheek
Bone Augmentation, Juvederm Ultra plus XC in treatment of
nasolabial folds and Juvederm Volift in Lip Enhancement).
- Evaluate proportion of population reporting with dermal
filler’s adverse effect and during the course of the study.
- Evaluate and compare long-term safety of Crosslinked HA
(Biotech’s Dermal filler and Juvederm Voluma XC,
Juvederm Ultra Plus XC and Juvederm Volift) up to 12
Months
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18.00 Year(s) 至 75.00 Year(s)（—）
- 性别
- All
入选标准
- •The patient must be ≥ 18 and ≤ 75 years of age.
- •The patient is willing and able to comply with the study protocol.
- •The patient is seeking soft tissue augmentation treatment on the face.
- •The patient needing Cheek bone Augmentation will be enrolled in arm 1 of the trial.
- •The patient with deep depression of the Nasolabial folds will be enrolled in arm 2 of the trial.
- •The patient needing Lip Enhancement will be enrolled in arm 3 of the trial.
- •The patient agrees to follow-up examinations out to 6 months post final treatment.
- •The patient has a pre-treatment Wrinkle Severity Score (WSS) ≥ 2 for bilateral NLF to be treated.
排除标准
- •At risk in term of precautions, warnings and contra-indication referred in the package insert of the study dermal fillers,
- •Who underwent previous injection of permanent filler in the injected area.
- •Pregnant/lactating women
- •Participation in any other Clinical trial.
- •Subjects who have an allergy to lidocaine, prilocaine or other amide-type anesthetic
- •Had a chemical peel at the NLF area within 4 weeks prior to study entry.
- •In addition, subjects were restricted from undergoing chemical peels at the NLF area for the duration of the study.
- •Had any treatment with Botox® injections: a) In the upper 1/3 of the face within 2 weeks prior to entry into the study, or b) In the lower 2/3 of the face within 24 weeks prior to entry.
- •In addition, subjects were restricted from receiving Botox injections in the face for the duration of the study.
- •Had a history of hypo- or hyperpigmentation of the skin.
- •Tolerance to antibiotics or corticosteroids.
- •Had any infection, unhealed wound, or active inflammatory process (e.g., skin eruptions such as cysts, pimples, rashes, or hives) at the injection site(s).
- •A known history of keloids or bleeding disorders.
- •Leukoderma (Vitiligo) or a family history of leukoderma or other pigmentary disorders.
- •Severe physical, neurological or mental disease.
结局指标
主要结局
The primary efficacy endpoint is responder rate in GAIS Score from Day 0 to 12 Months and
时间窗: Day 0 to 12 Months
study of the safety and severity of adverse events (AEs).
时间窗: Day 0 to 12 Months
次要结局
- To evaluate the Cheek bone Augmentation, the improvement in the Nasolabial(fold and Evaluate Lip Enhancement from Day 0 to 3, 6 and 12 Months)